Match!
Hilary D. Marston
National Institutes of Health
20Publications
12H-index
446Citations
Publications 21
Newest
#1Catharine I. Paules (Penn State Milton S. Hershey Medical Center)H-Index: 1
#2Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 3 authors...
10 CitationsSource
#2Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 3 authors...
Measles in 2019 — Going Backward Recent increases in measles cases in the United States mirror patterns in other countries that had previously eliminated the virus. This resurgence is all the more frustrating since the disease is entirely preventable through vaccination.
6 CitationsSource
#1Kirsten Vannice (WHO: World Health Organization)H-Index: 10
#2M. Cristina Cassetti (NIH: National Institutes of Health)H-Index: 6
Last.Philip R. Krause (CBER: Center for Biologics Evaluation and Research)H-Index: 28
view all 9 authors...
Abstract Since its peak in early 2016, the incidence of Zika virus (ZIKV) cases has declined to such low levels that Phase 3 field efficacy trials may be infeasible. While great progress was made to rapidly advance several vaccine candidates into Phase 1 and 2 clinical trials, in the absence of sustained viral transmission it may be difficult to evaluate the effectiveness of ZIKV vaccine candidates by conducting traditional clinical disease endpoint efficacy studies. However, ZIKV is still circu...
6 CitationsSource
#1Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
#2Carl W. Dieffenbach (NIH: National Institutes of Health)H-Index: 11
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 3 authors...
3 CitationsSource
#2Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 4 authors...
Tickborne Diseases The burden of tickborne diseases is growing substantially and seems likely to continue to do so. Prevention and management are hampered by suboptimal diagnostics, lack of treatment options for emerging viruses, and a paucity of vaccines.
16 CitationsSource
#1Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
#2Catharine I. Paules (NIH: National Institutes of Health)H-Index: 8
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 3 authors...
Monoclonal Antibodies for Infectious Diseases Research advances could facilitate use of monoclonal antibodies for emerging infectious diseases — in treatment of infected individuals, targeted prophylaxis to protect high-risk individuals, and targeted prophylaxis to interrupt transmission in average-risk populations.
17 CitationsSource
#1Catharine I. Paules (NIH: National Institutes of Health)H-Index: 8
#2Robert W. Eisinger (NIH: National Institutes of Health)H-Index: 7
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 4 authors...
4 CitationsSource
#1Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
#2Catharine I. Paules (NIH: National Institutes of Health)H-Index: 8
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 3 authors...
1 CitationsSource
#1Catharine I. Paules (NIH: National Institutes of Health)H-Index: 8
#2Hilary D. Marston (NIH: National Institutes of Health)H-Index: 12
Last.Anthony S. Fauci (NIH: National Institutes of Health)H-Index: 154
view all 5 authors...
Development of a universal influenza vaccine is a research priority for the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. To facilitate this goal, we convened a workshop in Rockville, Maryland to identify knowledge gaps in influenza research and develop strategies to fill them.
57 CitationsSource
The scientific feasibility of developing a safe, effective Zika vaccine doesn't ensure successful development. An efficient development pathway must be delineated, including better ways to evaluate vaccine candidates for intended target populations.
39 CitationsSource
123